Скачать или смотреть SIERRA: safety of durvalumab and tremelimumab in Asian patients with uHCC

Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, South Korea, discusses safety outcomes among Asian patients with unresectable hepatocellular carcinoma (uHCC) treated with first line STRIDE (single tremelimumab regular interval durvalumab) in the Phase IIIb SIERRA study (NCT05883644). Overall rates of treatment-related adverse events were consistent across clinical subgroups, with manageable immune-related toxicity and limited treatment discontinuation. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.